• UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    Tuesday May 10th 2022

  • Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME)

    Monday May 9th 2022

  • argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia

    Thursday May 5th 2022

  • reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a

    Tuesday May 3rd 2022

  • Mithra announces improved consolidated topline results from Donesta® Phase 3 studies and launch of recruitment for the extension of European study

    Thursday April 14th 2022

  • Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study

    Tuesday April 5th 2022

  • Aligos Therapeutics selects drug candidate ALG-097558, a potent ritonavir-free oral protease inhibitor for the treatment and prevention of COVID-19

    Tuesday April 5th 2022

  • Rejuvenate Biomed started a groundbreaking clinical trial and expands for future growth

    Tuesday March 29th 2022

  • Your news here?

  • Bone Therapeutics to strategically focus on lead cell therapy product ALLOB

    Tuesday March 29th 2022

  • Jyseleca® approved in Japan for ulcerative colitis

    Monday March 28th 2022

  • argenx announces positive topline Phase 3 data from ADAPT-SC study evaluating subcutaneous efgartigimod for generalized myasthenia gravis

    Tuesday March 22nd 2022


Strategic Partners